Yogen Saunthararajah is a Professor of Medicine, Staff Physician and Co-Leader of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center in Cleveland, a matrix Cancer Center of Cleveland Clinic and Case Western Reserve University.
Dr Saunthararajah graduated with Distinctions in Medicine and Surgery from the University of Wales College of Medicine and completed his training in hematology and oncology at the National Institutes of Health in Bethesda, Maryland.
Dr Saunthararajah’s research group looks for natural forces in diseased cells that can be leveraged for non-toxic, potently effective treatments – examples are exploiting paused silencing of the unmutated fetal hemoglobin gene to remedy sickle cell and β-thalassemia red blood cells, and releasing cancer cells to their intended terminal (non-dividing) specialized fates by enabling the commanders (master transcription factors) of such fates that cancers inherently highly express.
James Kazura is a Distinguished University Professor and Director of the Center for Global Health & Diseases at Case Western Reserve University School of Medicine. His efforts in basic and translational research are aimed at the development, testing, and implementation of cost-effective preventative and therapeutic interventions that improve the health of people in resource constrained areas of the tropics.
His disease-focuses include mosquito borne infectious diseases such as malaria and lymphatic filariasis, a parasitic worm that causes elephantiasis and genital pathology, and selected viral hemorrhagic fever viruses such as Rift Valley Fever. He and his collaborators in sub-Saharan Africa (primarily Kenya) and the South Pacific (primarily Papua New Guinea) have conducted field and laboratory research efforts funded by the National Institutes of Health and non-governmental organizations over the past 40 years.
Dr. Kazura has also served as the chair and a regular member of multiple NIH study sections and World Health Organization expert committees concerned with tropical infectious and non-infectious disease health issues. He is board certified in internal medicine and hematology, an elected member of the American Society of Clinical Investigation and American Association of Physicians, served as the President of the American Society of Tropical Medicine & Hygiene, and was Editor-in- Chief of the ASTMH journal.
Paul DiCorleto is the Vice President for Research and Sponsored Programs at Kent State. Previously, Paul was at Cleveland Clinic, where he served as the Sherwin-Page Chair of the Lerner Research Institute since 2002, and as chair of the Department of Molecular Medicine in the Case Western Reserve University School of Medicine since 2003.
DiCorleto has served on numerous Cleveland Clinic committees, including chair of the Lerner Research Institute Leadership Committee, chair of the Research Strategic Council, and as a member of the Board of Governors and Board of Trustees, Council of Institute Chairs, Capital Review Committee, Cleveland Clinic Innovations Commercialization Council and Industrial Advisory Board, and the Global Cardiovascular Innovation Center Commercialization Advisory Board and Board of Directors.
An award-winning scholar and invited lecturer, Paul has authored or co-authored more than 120 articles, papers and book chapters. Paul has chaired multiple NIH and American Heart Association review panels, as well as several national conferences on research into heart and vascular disease. He has served as president of the North American Vascular Biology Organization, and he is currently a member of its Scientific Advisory Board. He also serves as a member of the Association of American Medical Colleges’ Advisory Panel on Research and was elected a fellow of the American Association for the Advancement of Science in 2007.
Rick Panicucci is our distinguished clinical R&D expert. Rick joined WuXi AppTec in February 2015 as the Vice President of Pharmaceutical Development Services. In this capacity, Rick provides scientific leadership for 160 scientists in Developability, Formulation Development, and GMP Manufacturing and is responsible for the execution of all Parenteral and Oral dosage form programs.
He also maintains key client relationships and assesses new technologies through partnering or internal M&A capacity building. In addition to his position at WuXi, Rick currently serves as an Adjunct Professor at Massachusetts College of Pharmacy. Prior to WuXi, Rick was the Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015. His responsibilities included analytics, solid state chemistry and formulation development of all small molecule therapeutics in early development.
He also helped develop novel drug delivery technologies for small molecules and large molecules including siRNA. Rick has also led groups in Formulation and Research and Development at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb.
Rick received his Ph.D. in Physical Organic Chemistry from the University of Toronto and had two post-doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute.